| pubmed-article:18509353 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18509353 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:18509353 | lifeskim:mentions | umls-concept:C0038250 | lld:lifeskim |
| pubmed-article:18509353 | lifeskim:mentions | umls-concept:C1333568 | lld:lifeskim |
| pubmed-article:18509353 | lifeskim:mentions | umls-concept:C0023467 | lld:lifeskim |
| pubmed-article:18509353 | lifeskim:mentions | umls-concept:C1515654 | lld:lifeskim |
| pubmed-article:18509353 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:18509353 | lifeskim:mentions | umls-concept:C0683598 | lld:lifeskim |
| pubmed-article:18509353 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:18509353 | lifeskim:mentions | umls-concept:C1318444 | lld:lifeskim |
| pubmed-article:18509353 | lifeskim:mentions | umls-concept:C0205225 | lld:lifeskim |
| pubmed-article:18509353 | lifeskim:mentions | umls-concept:C1704788 | lld:lifeskim |
| pubmed-article:18509353 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:18509353 | pubmed:dateCreated | 2008-7-16 | lld:pubmed |
| pubmed-article:18509353 | pubmed:abstractText | Relapse in acute myeloid leukaemia (AML) is mediated by survival of leukaemic stem cells following remission-induction chemotherapy. It would therefore be useful to identify therapeutic agents that target leukaemic stem cells. We devised a flow cytometric chemosensitivity assay allowing 48 h culture of leukaemic blasts in a defined microenvironment followed by enumeration of viable CD34+CD38-CD123+ leukaemic stem and progenitor cells (LSPC). The assay was used to investigate the LSPC response to cytosine arabinoside (Ara-C) and to the FLT3 inhibitor AG1296. There was a 3.6-fold increase in Ara-C-treated LSPC survival under defined 'niche-like' conditions compared to culture without microenvironmental support. Nine AML samples with internal tandem duplications of FLT3 (FLT3/ITDs) were treated with AG1296. Three samples were very sensitive (>50% kill) and 4 were moderately sensitive (10-50% kill) in bulk suspension culture without microenvironmental support. However, under defined 'niche-like' conditions, the survival of LSPC was enhanced rather than inhibited by AG1296 treatment. We conclude that an interaction between LSPC and a defined in vitro microenvironment models a chemoresistant niche. Our data point to a need to investigate more novel chemotherapeutic agents under these stringent conditions to identify agents that may be suitable to target minimal residual disease in AML. | lld:pubmed |
| pubmed-article:18509353 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18509353 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18509353 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18509353 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18509353 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18509353 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18509353 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18509353 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18509353 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18509353 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18509353 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18509353 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18509353 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18509353 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18509353 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18509353 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18509353 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:18509353 | pubmed:issn | 1476-5551 | lld:pubmed |
| pubmed-article:18509353 | pubmed:author | pubmed-author:KüllikEE | lld:pubmed |
| pubmed-article:18509353 | pubmed:author | pubmed-author:RussellNN | lld:pubmed |
| pubmed-article:18509353 | pubmed:author | pubmed-author:JawadMM | lld:pubmed |
| pubmed-article:18509353 | pubmed:author | pubmed-author:MonyUU | lld:pubmed |
| pubmed-article:18509353 | pubmed:author | pubmed-author:SeedhouseCC | lld:pubmed |
| pubmed-article:18509353 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18509353 | pubmed:volume | 22 | lld:pubmed |
| pubmed-article:18509353 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18509353 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18509353 | pubmed:pagination | 1395-401 | lld:pubmed |
| pubmed-article:18509353 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:18509353 | pubmed:meshHeading | pubmed-meshheading:18509353... | lld:pubmed |
| pubmed-article:18509353 | pubmed:meshHeading | pubmed-meshheading:18509353... | lld:pubmed |
| pubmed-article:18509353 | pubmed:meshHeading | pubmed-meshheading:18509353... | lld:pubmed |
| pubmed-article:18509353 | pubmed:meshHeading | pubmed-meshheading:18509353... | lld:pubmed |
| pubmed-article:18509353 | pubmed:meshHeading | pubmed-meshheading:18509353... | lld:pubmed |
| pubmed-article:18509353 | pubmed:meshHeading | pubmed-meshheading:18509353... | lld:pubmed |
| pubmed-article:18509353 | pubmed:meshHeading | pubmed-meshheading:18509353... | lld:pubmed |
| pubmed-article:18509353 | pubmed:meshHeading | pubmed-meshheading:18509353... | lld:pubmed |
| pubmed-article:18509353 | pubmed:meshHeading | pubmed-meshheading:18509353... | lld:pubmed |
| pubmed-article:18509353 | pubmed:meshHeading | pubmed-meshheading:18509353... | lld:pubmed |
| pubmed-article:18509353 | pubmed:meshHeading | pubmed-meshheading:18509353... | lld:pubmed |
| pubmed-article:18509353 | pubmed:meshHeading | pubmed-meshheading:18509353... | lld:pubmed |
| pubmed-article:18509353 | pubmed:meshHeading | pubmed-meshheading:18509353... | lld:pubmed |
| pubmed-article:18509353 | pubmed:meshHeading | pubmed-meshheading:18509353... | lld:pubmed |
| pubmed-article:18509353 | pubmed:meshHeading | pubmed-meshheading:18509353... | lld:pubmed |
| pubmed-article:18509353 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18509353 | pubmed:articleTitle | Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment. | lld:pubmed |
| pubmed-article:18509353 | pubmed:affiliation | Division of Haematology, University of Nottingham, Nottingham, UK. | lld:pubmed |
| pubmed-article:18509353 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18509353 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18509353 | lld:pubmed |
